South African antitrust authorities ended an investigation into Johnson & Johnson and its Janssen subsidiary over “extreme pricing” of a lifesaving tuberculosis drug after the businesses took steps to decrease the price and widen entry to the medication.
In a quick assertion, the Competitors Fee defined that J&J and Janssen agreed to not implement a so-called secondary patent on bedaquiline, which can be offered below the model title Sirturo, a step that makes it potential for generic corporations to provide a lower-cost model. On the identical time, the businesses agreed to decrease the value charged to the Nationwide Division of Well being by about 40%.
The Competitors Fee maintained that the value is in step with what the businesses are providing the International Drug Facility, which is the world’s largest procurer of tuberculosis medicines and diagnostics. In consequence, the regulator agreed to not pursue an anti-competitive criticism, which was filed final September, earlier than a tribunal.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and networking platform entry.
Have already got an account? Log in
Have already got an account? Log in
View All Plans
